The price of CDXS is predicted to go up -3.72%, based on the high correlation periods with CIO. The similarity of these two price pattern on the periods is 95.84%.

CDXS

CIO

Down: -3.72%Similarity: 95.84%

CDXS Revenue Forecast

CDXS EPS Forecast

CDXS FAQs

What is bull’s view on CDXS?

CDXS stock has bullish potential due to its recent strategic licensing agreement with Alphazyme LLC, which could drive revenue growth by leveraging its enzyme portfolio. Insider confidence is evident, with significant purchases like the recent acquisition of 45,000 shares by a 10% owner, signaling optimism about the company's future. Analysts like Cantor Fitzgerald maintain a "Buy" rating with a price target of $11, suggesting a substantial upside from its current levels.

What is bear's view on CDXS?

CDXS stock faces bearish pressure due to declining R&D revenues and uncertainty in executing strategic partnerships, with TD Cowen maintaining a Hold rating and a $3.00 price target. Insider buying activity and extended cash runway until 2027 are positive, but profitability challenges and mixed revenue growth weigh on sentiment. The stock's current market position suggests limited upside unless significant operational improvements are achieved.